Global BD&L and Alliance Management

Business Development & Licensing

The MorphoSys Business Development & Licensing team approaches collaborations and licensing deals with the aim of addressing the needs and aligning the contributions of both partners. The ultimate goal for our award-winning BD&L team is to define the combined strengths of such partnerships to create promising therapeutics which make a difference for people suffering from diseases with high unmet medical need. Harboring sound scientific, clinical and drug development knowledge together with an industry-focused expertise in business intelligence, the team lays the groundwork for identifying and evaluating appropriate partners whose assets and expertise present a beneficial and complementary asset to the vast company portfolio.

Currently, we are actively looking for compounds in clinical development that fit into the MorphoSys portfolio. Primary focus are biologics in hemato-oncology and solid tumors. In addition, the team supports MorphoSys’ Research Organization in identifying new targets and technologies to complement the early stage pipeline.

The BD&L Teams are your primary contact for your target, technology and program offers as well in case of interest in our technologies and compounds.

Dr. Anja Hanisch, Senior Director Licensing

Dr. Monika Bähner, Senior Director Search & Evaluation / In-Licensing

Alliance Management

The negotiation and management of partnerships has been MorphoSys’ foundation and will continue to play an important role also in our future to maximize value creation and serving patients worldwide. The teams are closely integrated within Global BD&L to ensure a smooth transition from contract negotiations into the successful execution of the partnership.

During the complete alliance lifecycle, these teams provide continuous support across all functions, and ensure that respective duties are performed and the partnership is evolving to the full satisfaction of both sides. Our partners benefit from this unit’s performance by receiving the high-quality therapeutic input and reliable technology support they expect from MorphoSys. Not least due to its careful monitoring and coordination work, MorphoSys has one of the broadest and most successful therapeutic pipelines with partners in the industry.

As MorphoSys transitioned into a fully integrated biopharmaceutical company with the establishment of our US-based commercial team in Boston, our expert team was expanded to support also late-stage development and commercialization alliances on both continents.